0.975
-0.07 (-6.25%)
| Penutupan Terdahulu | 1.04 |
| Jumlah Dagangan | 521,050 |
| Harga / Buku (P/B) | 4.54 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.830 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.50% |
| Nisbah Semasa (MRQ) | 2.22 |
| Aliran Tunai Operasi (OCF TTM) | -19.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.84 M |
| Pulangan Atas Aset (ROA TTM) | -97.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -290.21% |
AISkor Stockmoo
| Nilai 30% | -2.1 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Masa 30% | -4.1 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Corak Lilin info | NA |
| Aliran bagi Tempoh Pegangan Anda info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Berita info | NA |
| Wang Pintar 20% | -1.4 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih -0.52% daripada saham dalam pemfailan 13F terkini: 23 pemegang menambah, 18 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +39.2% dari 31 Aug hingga 30 Oct 2026, 5.5 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menurun. info | |
| Skor Akhir | -2.99 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Gain Therapeutics, Inc. | Bercampur | Bercampur |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| GANX | - | - | - | 4.54 |
| TRML | 1 B | - | - | 4.76 |
| TECH | - | 0.44% | - | 5.28 |
| MLTX | - | - | - | 2.79 |
| VKTX | - | - | - | 6.33 |
| VSTM | - | - | - | 76.50 |
|
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.78% |
| % Dimiliki oleh Institusi | 8.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 30 Sep 2026 | 566,645 |
| Dme Capital Management, Lp | 30 Jun 2026 | 566,130 |
| Cresset Asset Management, Llc | 30 Jun 2026 | 160,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 20.51%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 23 | 865,600 |
| Berkurang | 18 | 1,105,450 |
| Baharu | 11 | 427,858 |
| Dijual habis | 6 | 422,295 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 3,891,227 | 5.5 |
| 15 Oct 2026 | 3,191,453 | 6.5 |
| 30 Sep 2026 | 3,056,188 | 5.9 |
| 15 Sep 2026 | 2,887,151 | 8.9 |
| 31 Aug 2026 | 2,795,819 | 7.7 |
| 14 Aug 2026 | 2,952,391 | 4.9 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
| 10 Nov 2026 | Yahoo Finance |
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the… |
| 05 Nov 2026 | Yahoo Finance |
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two… |
| 08 Oct 2026 | Yahoo Finance |
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the… |
| 01 Oct 2026 | Yahoo Finance |
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants with both high and low baseline levels of GluSph… |
| 29 Sep 2026 | Yahoo Finance |
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at… |
| 17 Sep 2026 | Yahoo Finance |
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President… |
| 25 Aug 2026 | Yahoo Finance |
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President… |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |